Drug intelligence / Profile preview

HPV16 E7 peptide-pulsed autologous dendritic cells

Development stage: Phase 1
Modality: Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

HPV16 E7 peptide-pulsed autologous dendritic cells is a therapeutic cancer vaccine that uses a patient's own dendritic cells loaded with HPV16 E7 peptides to stimulate an immune response against HPV-related cancers. The vaccine is created by collecting peripheral blood leukocytes from patients, generating dendritic cells, pulsing them with HPV16 E7 peptides, and then reinjecting these cells to stimulate cytotoxic T lymphocyte responses against HPV-infected cancer cells. This approach aims to induce antitumor immunity in patients with HPV16-positive cancers, particularly cervical cancer.

Other names: HPV16 E7 peptide-pulsed autologous dendritic cell vaccineHPV-16 E7 peptide-pulsed autologous dendritic cell vaccineHPV 16 E7 peptide-pulsed autologous dendritic cell vaccineHPV16 E7-loaded dendritic cell vaccineHPV-16 E7-loaded dendritic cell vaccineHPV 16 E7-loaded dendritic cell vaccineautologous HPV-16 E7-pulsed dendritic cell vaccineHPV-16 E7-pulsed DC vaccineHPV16 E7-pulsed DC vaccineHPV 16 E7-pulsed DC vaccine

Targets

HPV16 E7 TCR (HPV16 E7-specific T-cell receptor)Major histocompatibility complex class I peptide-binding groove on autologous dendritic cells

Beyond the preview

Go deeper on HPV16 E7 peptide-pulsed autologous dendritic cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HPV16 E7 peptide-pulsed autologous dendritic cells.